BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Wilton J, Wong S, Yu A, Ramji A, Cook D, Butt ZA, Alvarez M, Binka M, Darvishian M, Jeong D, Bartlett SR, Pearce ME, Adu PA, Yoshida EM, Krajden M, Janjua NZ. Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study. Open Forum Infect Dis. 2020;7:ofaa055. [PMID: 32154326 DOI: 10.1093/ofid/ofaa055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, Wong J, Rossi C, Butt ZA, Bartlett S, Pearce ME, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua NZ. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat 2020;27:243-60. [PMID: 31664755 DOI: 10.1111/jvh.13228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
3 Yasseen AS 3rd, Kwong JC, Feld JJ, Janjua NZ, Greenaway C, Lapointe-Shaw L, Sherman M, Mazzulli T, Kustra R, MacDonald L, Sander B, Crowcroft NS. Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver Int 2021;41:1775-88. [PMID: 33655665 DOI: 10.1111/liv.14840] [Reference Citation Analysis]
4 Egerman RS. New Antiviral Agents for Treatment of Hepatitis C. Clin Obstet Gynecol 2019;62:823-34. [PMID: 31094712 DOI: 10.1097/GRF.0000000000000457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. [DOI: 10.1111/apt.15297] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
6 Yasseen AS 3rd, Kwong JC, Kustra R, Holder L, Chung H, Macdonald L, Janjua NZ, Mazzulli T, Feld J, Crowcroft NS. Validating viral hepatitis B and C diagnosis codes: a retrospective analysis using Ontario's health administrative data. Can J Public Health 2021;112:502-12. [PMID: 33417192 DOI: 10.17269/s41997-020-00435-x] [Reference Citation Analysis]
7 Socías ME, Ti L, Wood E, Nosova E, Hull M, Hayashi K, Debeck K, Milloy MJ. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver Int 2019;39:1400-7. [PMID: 30653809 DOI: 10.1111/liv.14043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
8 Mittal A, Kosinski KC, Stopka TJ. HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016. Harm Reduct J 2019;16:44. [PMID: 31288811 DOI: 10.1186/s12954-019-0314-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lanièce Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferrière V, Cooper CL, Walmsley S, Cox J, Wong A, Klein MB; Canadian Coinfection Cohort investigators. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Int J Drug Policy 2022;103:103627. [PMID: 35218989 DOI: 10.1016/j.drugpo.2022.103627] [Reference Citation Analysis]
10 Pearce ME, Yu A, Alvarez M, Bartlett SR, Binka M, Jeong D, Clementi E, Adu P, Wilton J, Yoshida EM, Pick N, Buxton JA, Wong J, Jassem A, Krajden M, Janjua NZ. Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019. PLoS One 2020;15:e0244575. [PMID: 33382774 DOI: 10.1371/journal.pone.0244575] [Reference Citation Analysis]
11 Pearce ME, Jongbloed K, Demerais L, MacDonald H, Christian WM, Sharma R, Pick N, Yoshida EM, Spittal PM, Klein MB. "Another thing to live for": Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities. Int J Drug Policy 2019;74:52-61. [PMID: 31525640 DOI: 10.1016/j.drugpo.2019.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
12 Pandey M, Konrad S, Reed N, Ahenakew V, Isbister P, Isbister T, Gallagher L, Campbell T, Skinner S. Liver health events: an indigenous community-led model to enhance HCV screening and linkage to care. Health Promot Int 2021:daab074. [PMID: 34125199 DOI: 10.1093/heapro/daab074] [Reference Citation Analysis]
13 Jacob J, Goodyear T, Coulaud PJ, Hoong P, Ti L, Knight R. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada. Can J Public Health 2021. [PMID: 34115340 DOI: 10.17269/s41997-021-00535-2] [Reference Citation Analysis]
14 Lapointe HR, Dong W, Dong WWY, Kirkby D, Woods C, Poon AFY, Howe AYM, Harrigan PR, Brumme CJ. Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay. Viruses 2021;13:1721. [PMID: 34578305 DOI: 10.3390/v13091721] [Reference Citation Analysis]
15 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
16 Gander S, Morris A, Materniak S. An Evaluation of Hepatitis C Screening in Infants and Children Born to Seropositive Mothers in Saint John, New Brunswick. Cureus 2021;13:e17377. [PMID: 34584787 DOI: 10.7759/cureus.17377] [Reference Citation Analysis]
17 Gouvêa AFTB, Filho RC, Machado DM, Bononi do Carmo F, Beltrão SV, Sampaio L, de Moraes-Pinto MI, Succi RCM. Assessment of liver disease by non-invasive methods in perinatally infected Brazilian adolescents and young adults living with Human Immunodeficiency Virus (HIV). Braz J Infect Dis 2021;25:101589. [PMID: 34147474 DOI: 10.1016/j.bjid.2021.101589] [Reference Citation Analysis]
18 Sirpal S, Chandok N. Barriers to hepatitis C diagnosis and treatment in the DAA era: Preliminary results of a community-based survey of primary care practitioners. CanLivJ 2022;5:96-100. [DOI: 10.3138/canlivj-2021-0032] [Reference Citation Analysis]
19 Alduraywish A, Ragheb M, Taher I, Louis N, Aldossari K, Kishk R. Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study. Scand J Gastroenterol 2020;55:963-9. [PMID: 32649843 DOI: 10.1080/00365521.2020.1790649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Elder K, Turner KA, Cosgrove L, Lexchin J, Shnier A, Moore A, Straus S, Thombs BD. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ 2020;192:E617-25. [PMID: 32538799 DOI: 10.1503/cmaj.191737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
21 Shapiro H, Zaman L, Kennedy VL, Dean N, Yudin MH, Loutfy M. Managing and preventing blood-borne viral infection transmission in assisted reproduction: a Canadian Fertility and Andrology Society clinical practice guideline. Reprod Biomed Online 2020;41:203-16. [PMID: 32546334 DOI: 10.1016/j.rbmo.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada. Int J Drug Policy 2021;88:102738. [PMID: 32278651 DOI: 10.1016/j.drugpo.2020.102738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
23 Gagné M, Têtu I, Grégoire J, Moisan J. Adherence and sustained virologic response among vulnerable people initiating an hepatitis C treatment at a nurse-led clinic: A non-experimental prospective cohort study based on clinical records. International Journal of Nursing Studies Advances 2021;3:100029. [DOI: 10.1016/j.ijnsa.2021.100029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nouch S, Gallagher L, Erickson M, Elbaharia R, Zhang W, Wang L, Bacani N, Kason D, Kleban H, Knebel L, Hall D, Barrios R, Hull M. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. International Journal of Drug Policy 2018;59:76-84. [DOI: 10.1016/j.drugpo.2018.06.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
25 Pearce ME, Bartlett SR, Yu A, Lamb J, Reitz C, Wong S, Alvarez M, Binka M, Velásquez Garcia H, Jeong D, Clementi E, Adu P, Samji H, Wong J, Buxton J, Yoshida E, Elwood C, Sauve L, Pick N, Krajden M, Janjua NZ. Women in the 2019 hepatitis C cascade of care: findings from the British Columbia Hepatitis Testers cohort study. BMC Womens Health 2021;21:330. [PMID: 34511082 DOI: 10.1186/s12905-021-01470-7] [Reference Citation Analysis]
26 Hamadeh A, Feng Z, Krahn M, Wong WWL. A model-based framework for chronic hepatitis C prevalence estimation. PLoS One 2019;14:e0225366. [PMID: 31751393 DOI: 10.1371/journal.pone.0225366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hamadeh A, Haines A, Feng Z, Thein HH, Janjua NZ, Krahn M, Wong WWL. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat 2020;27:1419-29. [PMID: 32810886 DOI: 10.1111/jvh.13373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Makarenko I, Artenie A, Hoj S, Minoyan N, Jacka B, Zang G, Barlett G, Jutras-Aswad D, Martel-Laferriere V, Bruneau J. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs? Int J Drug Policy 2019;72:69-76. [PMID: 31010749 DOI: 10.1016/j.drugpo.2019.04.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
29 Wong WWL, Haines A, Bremner KE, Yao Z, Calzavara A, Mitsakakis N, Kwong JC, Sander B, Thein HH, Krahn MD. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open 2021;9:E167-74. [PMID: 33688024 DOI: 10.9778/cmajo.20200162] [Reference Citation Analysis]
30 Kronfli N, Buxton JA, Jennings L, Kouyoumdjian F, Wong A. Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be? CanLivJ 2019;2:171-83. [DOI: 10.3138/canlivj.2019-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Pasqualotto AC, Almeida CS, Kliemann DA, Barcellos GB, Queiroz-Telles F, Abdala E, Resende M, Batista FP, Vidal JE, Rocha J, Raboni SM, Cimerman S, Gales AC. Top 10 evidence-based recommendations from the Brazilian Society of Infectious Diseases for the Choosing Wisely Project. Braz J Infect Dis 2019;23:331-5. [PMID: 31562852 DOI: 10.1016/j.bjid.2019.08.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Haines AG, Mendlowitz AB, Wong WW, Krahn M. Strategies to achieve population control of HCV infection: results of a multidisciplinary focus group. CanLivJ 2020;3:224-31. [DOI: 10.3138/canlivj-2019-0017] [Reference Citation Analysis]
33 Cooper CL, Galanakis C, Donelle J, Kwong J, Boyd R, Boucher L, Kendall CE. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis 2019;19:712. [PMID: 31438873 DOI: 10.1186/s12879-019-4315-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
34 Greenaway E, Biondi MJ, Feld JJ, Ling SC. Hepatitis C virus infection in mothers and children. CanLivJ 2019;2:210-24. [DOI: 10.3138/canlivj.2019-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Ganta NM, Gedda G, Rathnakar B, Satyanarayana M, Yamajala B, Ahsan MJ, Jadav SS, Balaraju T. A review on HCV inhibitors: Significance of non-structural polyproteins. Eur J Med Chem 2019;164:576-601. [PMID: 30639895 DOI: 10.1016/j.ejmech.2018.12.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
36 Lin JJ, Loucks CM, Trueman JN, Drögemöller BI, Wright GEB, Yoshida EM, Ford JA, Lee SS, Kim RB, Al-Judaibi B, Schwarz UI, Ramji A, Tam E, Ross CJ, Carleton BC. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Biomed Pharmacother 2021;143:112195. [PMID: 34562771 DOI: 10.1016/j.biopha.2021.112195] [Reference Citation Analysis]
37 Gandhi CR. Pro- and Anti-fibrogenic Functions of Gram-Negative Bacterial Lipopolysaccharide in the Liver. Front Med (Lausanne) 2020;7:130. [PMID: 32373617 DOI: 10.3389/fmed.2020.00130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bouzanis K, Joshi S, Lokker C, Pavalagantharajah S, Qiu Y, Sidhu H, Mbuagbaw L, Qutob M, Henedi A, Levine MAH, Lennox R, Tarride JE, Kalina D, Alvarez E. Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review. BMJ Open 2021;11:e047511. [PMID: 34556508 DOI: 10.1136/bmjopen-2020-047511] [Reference Citation Analysis]
39 Folkema A, Wang HL, Wright K, Hirji MM, Andonov A, Bromley K, Ludwig C, MacArthur A. An outbreak of hepatitis C virus attributed to the use of multi-dose vials at a colonoscopy clinic, Waterloo Region, Ontario. Can Commun Dis Rep 2021;47:224-31. [PMID: 34035670 DOI: 10.14745/ccdr.v47i04a07] [Reference Citation Analysis]
40 Lanièce Delaunay C, Godin A, Kronfli N, Panagiotoglou D, Cox J, Alary M, Klein MB, Maheu-Giroux M. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030? Int J Drug Policy 2021;:103343. [PMID: 34215459 DOI: 10.1016/j.drugpo.2021.103343] [Reference Citation Analysis]
41 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj-2019-0002] [Reference Citation Analysis]
42 Hsieh YC, Lin CL, Hung CH, Chen CH, Tung SY, Lin CY, Hu TH, Lu SN, Chien RN, Sheen IS. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. J Viral Hepat 2020;27:505-13. [PMID: 32039536 DOI: 10.1111/jvh.13262] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Biondi MJ, Hirode G, Capraru C, Vanderhoff A, Karkada J, Wolfson-stofko B, Smookler D, Friedman SM, Bates K, Mazzulli T, Juan JV, Shah H, Hansen BE, Feld JJ, Janssen HL. Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. CanLivJ. [DOI: 10.3138/canlivj-2021-0036] [Reference Citation Analysis]
44 Høj SB, Jacka B, Minoyan N, Artenie AA, Bruneau J. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. Int J Drug Policy 2019;72:11-23. [PMID: 31003825 DOI: 10.1016/j.drugpo.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
45 Sahakyan Y, Lee-Kim V, Bremner KE, Bielecki JM, Krahn MD. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. J Viral Hepat 2021;28:739-54. [PMID: 33556225 DOI: 10.1111/jvh.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kronfli N, Dussault C, Bartlett S, Fuchs D, Kaita K, Harland K, Martin B, Whitten-nagle C, Cox J. Disparities in hepatitis C care across Canadian provincial prisons: Implications for hepatitis C micro-elimination. CanLivJ 2021;4:292-310. [DOI: 10.3138/canlivj-2020-0035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Adv Ther 2019;36:3458-70. [PMID: 31646465 DOI: 10.1007/s12325-019-01123-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Rai M, Lowe C, Flemming JA. Screening for hepatitis C in an outpatient endoscopy unit. CanLivJ 2021;4:311-6. [DOI: 10.3138/canlivj-2020-0038] [Reference Citation Analysis]
49 Elwood C, Sauve LJ, Pick N. Preventing vertical transmission of HCV in Canada. CMAJ 2019;191:E650-1. [PMID: 31209131 DOI: 10.1503/cmaj.181662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Alvarez E, Joshi S, Lokker C, Wang A, Pavalagantharajah S, Qiu Y, Sidhu H, Mbuagbaw L, Qutob M, Henedi A, Levine M, Lennox R, Tarride JE, Kalina D. Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol. BMJ Open 2020;10:e035188. [PMID: 32792428 DOI: 10.1136/bmjopen-2019-035188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Lapointe-Shaw L, Chung H, Sander B, Kwong JC, Holder L, Cerocchi O, Austin PC, Feld JJ. Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. Liver Int 2021;41:33-47. [PMID: 32956567 DOI: 10.1111/liv.14670] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Tadrous M, Mason K, Dodd Z, Guyton M, Powis J, Mccormack D, Gomes T. Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. CanLivJ 2021;4:51-8. [DOI: 10.3138/canlivj-2020-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Kronfli N, Dussault C, Klein MB, Lebouché B, Sebastiani G, Cox J. The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. CMAJ Open 2019;7:E674-9. [PMID: 31796509 DOI: 10.9778/cmajo.20190068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
54 Chan J, Kim JJ, Barrett BK, Hamadeh A, Feld JJ, Wong WWL. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat 2021;28:260-7. [PMID: 33065774 DOI: 10.1111/jvh.13419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]